Articles From: QCR Holdings, Inc. Announces Net Income of $4.1 Million for the Third Quarter of 2014 to Qlik and Intuit Partner to Deliver Robust Accounting Analytics Solutions


2014/12/8
Qdoba ® today introduced its newest permanent addition to the menu – Smothered Burritos, which feature three new smothered sauces that go inside and over-the-top with flavor, literally, to give guests a new way to experience burritos.
Sign-up for Qdoba® “Smothers” Menu with New Line of Smothered Burritos and Sauces investment picks
2015/1/21
0740 GMT [Dow Jones]--Oil prices have neared their bottom at $46 a barrel, says Kenneth Hersch, Chief Executive Officer of NGP Energy Capital Management, an oil and gas focused private-equity firm.
Sign-up for QE is Good for Europe but Mixed for Deutsche Bank -2- investment picks
DENVER , Oct.
Sign-up for QEP Midstream Partners, LP Announces Quarterly Distribution investment picks
QEP Resources, Inc. (NYSE: QEP)(“QEP” or the “Company”) today announced that members of the Company’s senior management will participate in the upcoming Capital One Securities, Inc. Energy Conference on Wednesday, December 10, 2014 at 2:20 p.m. ET (12:20 p.m. MT). A link to the webcast and a copy of the presentation will be available at www.qepres.com .
Sign-up for QEP Resources Announces Participation in an Upcoming Investor Conference investment picks
QEP Resources, Inc. (NYSE: QEP)(“QEP” or the “Company”) today announced that its wholly owned subsidiary, QEP Field Services Company, has completed the sale of its midstream business, including the Company's ownership interest in QEP Midstream Partners, LP (NYSE:QEPM, “QEPM”), to Tesoro Logistics LP in an all cash transaction valued at $2.5 billion, including $230 million to refinance debt at QEPM.
Sign-up for QEP Resources Completes Sale of Its Midstream Business investment picks
QEP Resources, Inc. (NYSE:QEP) ("QEP" or the "Company") today reported third quarter 2014 financial and operating results.
Sign-up for QEP Resources Reports Third Quarter 2014 Financial and Operating Results investment picks
QEP Resources, Inc. (NYSE: QEP), a leading independent natural gas and crude oil exploration and production company, today announced that its Board of Directors approved a quarterly cash dividend of $0.02 per share of common stock, payable on December 5, 2014, to shareholders of record on November 14, 2014.
Sign-up for QEP Resources, Inc. Declares Quarterly Cash Dividend investment picks
2015/1/11
HILDEN , Germany and BEVERLY, Massachusetts , January 11, 2015 /PRNewswire/ -- Enzymatics products used in 80% of all global NGS sequencing reactions Strengthens QIAGEN's universal NGS product offering and strategy to offer complete NGS workflows from sample to insight Adds comprehensive R&D, manufacturing, formulation and analytical capabilities in enzymology Strategic partnership formed with ArcherDX, including technology and distribution rights to proprietary Archer NGS panel technology QIAGEN reaffirms fourth-quarter and full-year 2014 adjusted net sales guidance; charges to be taken related to acquisition and other restructuring activities QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Prime Standard QIA) today announced the acquisition of the Enzyme Solutions Unit of Enzymatics, a world leader in the development, manufacturing, and OEM supply of enzymes essential
Sign-up for QIAGEN Acquires Enzymatics Enzyme Solutions Unit, a Leading Enabler of NGS Applications investment picks
2014/10/28
HILDEN , Germany and TOKYO , October 28, 2014 /PRNewswire/ -- First two programs aim to create tests to aid in cancer treatment with Astellas compounds under development QIAGEN Personalized Healthcare pipeline expands with novel assay targeting FGFR mutations Partnership provides options for collaboration across therapeutic areas, sample types and testing technologies QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a master collaboration agreement with Astellas Pharma Inc., an R&D-driven global pharmaceutical company headquartered in Japan , to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases.
Sign-up for QIAGEN Announces Broad Agreement With Astellas Pharma to Develop Companion Diagnostics investment picks
HILDEN , Germany , January 12, 2015 /PRNewswire/ -- QIAGEN's circulating tumor DNA test is now CE-IVD marked to assess EGFR mutation status in non-small cell lung cancer (NSCLC) patients based on plasma samples therascreen EGFR RGQ Plasma PCR kit helps physicians to identify patients who could benefit from treatment with IRESSA when tumor tissue sample is not evaluable QIAGEN pioneering the use of liquid biopsy-based companion diagnostics as a less-invasive option to complement surgical biopsies for genomic profiling of cancers QIAGEN (NASDAQ: QGEN; Frankfurt , Prime Standard: QIA) announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess an important genomic mutation in patients with non-small cell lung cancer (NSCLC), the most common form of this cancer.
Sign-up for QIAGEN Announces First-ever Regulatory Registration of a Lung Cancer Companion Diagnostic Based on Liquid Biopsies investment picks
2014/10/28
HILDEN , Germany and BARCELONA, Spain , October 28, 2014 /PRNewswire/ -- New WHO guidelines launched for prevention include screening and treating for latent TB infection to avert progression to active disease, supporting the implementation of the Post-2015 strategy QIAGEN will support implementation of new guidelines with awareness campaigns and educational programs , improved access to QuantiFERON ® -TB Gold , research support and other collaborative efforts QIAGEN's QuantiFERON ® -TB Gold, the new standard for accuracy in latent TB infection diagnosis, continues to gain adoption in TB control programs worldwide QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced its support for the implementation of new guidelines presented today by the World Health Organization (WHO) as part of its Post-2015 Global Tuberculosis Strategy
Sign-up for QIAGEN Applauds Inclusion of Screening and Treatment for Latent Infection in WHO's Post-2015 Global Strategy to End Tuberculosis investment picks
2015/1/8
HILDEN , Germany and GERMANTOWN, Maryland , January 8, 2015 /PRNewswire/ -- Ongoing growth with 250 new QIAsymphony placements in 2014 Five FDA approvals and clearances achieved in 2014, including artus HSV-1/2 QS-RGQ MDx Kit QIAGEN affirms goal for more than 1,500 cumulative QIAsymphony placements by year-end 2015 and further test menu expansion QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that it had exceeded its goal for 250 new placements of the QIAsymphony modular automation solution in 2014, bringing the total number of cumulative placements to more than 1,250 at year-end.
Sign-up for QIAGEN Exceeds 2014 Goal to Achieve 1,250 Cumulative QIAsymphony System Placements and Expands artus U.S. Test Menu investment picks
2015/1/16
VENLO, The Netherlands , January 16, 2015 /PRNewswire/ -- QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans to release its report on results for the fourth quarter and full year 2014 on Wednesday, January 28 , at 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). Also as previously announced, a conference call is planned for Thursday, January 29 , at 15:30 CET / 9:30 ET that will include remarks by Peer M.
Sign-up for QIAGEN N.V. to Report Fourth Quarter and Full-Year 2014 Results investment picks
2014/10/29
VENLO, The Netherlands , October 29, 2014 /PRNewswire/ -- Achieved Q3 2014 targets: Adjusted net sales of $336.8 million (+4% CER); adjusted operating income of $84.8 million , a 25% margin; and adjusted EPS of $0.27 Adjusted net sales rise approximately 10% CER excluding U.S. HPV business Growth drivers contribute about 30% of total sales, delivering more than 20% CER growth and creating solid foundation for future expansion Free cash flow rises 18% to $72 million QIAGEN reaffirms 2014 expectations for higher adjusted net sales and earnings QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the third quarter and first nine months of 2014, reaffirming full-year expectations announced in January 2014 for improvements in adjusted net sales and earnings.
Sign-up for QIAGEN Reports Results for Third Quarter and First Nine Months of 2014 investment picks
2014/11/11
HILDEN , Germany , and MANCHESTER, England , November 11, 2014 /PRNewswire/ -- Master collaboration agreement is a framework for developing and commercializing QIAGEN companion diagnostics, paired with new or existing products New agreement provides options across therapeutic areas Collaboration adds to QIAGEN's more than 20 projects with pharma companies for development of blood- or tissue-based biomarker tests to guide treatments QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a master collaboration agreement with the Swiss pharmaceutical company Novartis AG to enable the development and commercialization of companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds in its development pipeline.
Sign-up for QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics investment picks
2014/12/4
HILDEN , Germany and GERMANTOWN, Maryland , December 4, 2014 /PRNewswire/ -- New molecular diagnostic test detects but does not differentiate all existing strains of Ebola virus Partnership with altona Diagnostics adds to portfolio of QIAGEN products already in use outside the United States by research and clinical laboratories for Ebola diagnostics and research QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it will offer global distribution of the altona Diagnostics RealStar ® Ebolavirus RT-PCR Kit 1.0 after the U.S. Food and Drug Administration amended, on November 26, 2014 to permit authorized distribution and use in US and certain non-US laboratories, an Emergency Use Authorization (EUA) originally issued on November 10, 2014 , for this kit.
Sign-up for QIAGEN to Distribute altona Diagnostic's RealStar® Ebolavirus RT-PCR Kit 1.0, Recently Authorized by the FDA for Emergency Use investment picks
BEIJING , Dec.
Sign-up for Qihoo 360 Announces Changes to Board of Directors investment picks
BEIJING , Dec.
Sign-up for Qihoo 360 Announces Strategic Partnership with Coolpad investment picks
BEIJING , Nov.
Sign-up for Qihoo 360 Reports Third Quarter 2014 Unaudited Financial Results investment picks
Total Adjusted Net Revenue Increases 47% to RUB 2,379 Million MOSCOW, Nov.
Sign-up for QIWI Announces Third-Quarter 2014 Results investment picks
MOSCOW, Oct.
Sign-up for QIWI Kiosks Will Be Installed in "Monetka" Supermarkets investment picks
MOSCOW, Nov.
Sign-up for QIWI Universe Demo Day -- a Story of Success investment picks
-- 3Q14 Revenue increased by 3.2% to $61.1 million from $59.2 million in 3Q13 -- --
Sign-up for QKL Stores Inc. Announces Third Quarter 2014 Financial Results investment picks
-- 3Q14 Revenue increased by 3.2% to $61.1 million from $59.2 million in 3Q13 -- --
Sign-up for QKL Stores Inc. Announces Third Quarter 2014 Financial Results investment picks
Qlik® (NASDAQ: QLIK), a leader in data discovery, today announced that Intuit Inc. has integrated QlikView® into QuickBooks Enterprise, to provide advanced analytics for its subscribers.
Sign-up for Qlik and Intuit Partner to Deliver Robust Accounting Analytics Solutions investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: QCR Holdings, Inc. Announces Net Income of $4.1 Million for the Third Quarter of 2014 to Qlik and Intuit Partner to Deliver Robust Accounting Analytics Solutions
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent